Araclon Biotech S.L.

Araclon Biotech S.L. and its majority owner Grifols, S.A. are continuing to analyze Phase II clinical trial results for ABvac40, an active vaccine against the amyloid-beta 40 peptide, in the treatm

Industry executives and biopharmaceutical analysts are reluctant to say that the failure of Eli Lilly & Co. ’s solanezumab in a third Phase III clinical trial is the end of the road for the amyloid

Device Transactions Medical device companies raised a total of $1.1 billion during the first quarter of 2012, a 40% increase over Q4 2011’s $800 million, and a much stronger start to the year than 201

IN VITRO DIAGNOSTICS Mergers & Acquisitions Abingdon Health Ltd. Molecular Vision Ltd. Abingdon Health Ltd. has purchased a 50.1% equity stake in fellow private diagnostics firm Molecular Vision